CareDx, Inc. is a commercial stage company that develops markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a patient�s lifetime. The Company�s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a blood-based test used to monitor heart transplant recipients for acute cellular rejection. AlloMap is a non-invasive method recommended in the International Society for Heart and Lung Transplantation (ISHLT), patient care guidelines for surveillance of heart transplant rejection in non-infants. The Company develops and provides a diagnostic surveillance testing solution for organ transplant recipients. Its commercial testing solution, AlloMap, uses gene expression technology to aid in the identification of heart transplant recipients at low risk of rejection.